The estimated Net Worth of Peter J Mariani is at least $2.58 Миллион dollars as of 11 December 2023. Mr. Mariani owns over 12,500 units of Axogen stock worth over $844,648 and over the last 9 years he sold AXGN stock worth over $1,190,413. In addition, he makes $548,032 as Chief Financial Officer at Axogen.
Peter has made over 14 trades of the Axogen stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 12,500 units of AXGN stock worth $93,750 on 11 December 2023.
The largest trade he's ever made was selling 75,683 units of Axogen stock on 30 October 2020 worth over $939,226. On average, Peter trades about 9,595 units every 87 days since 2016. As of 11 December 2023 he still owns at least 63,603 units of Axogen stock.
You can see the complete history of Mr. Mariani stock trades at the bottom of the page.
Peter J. Mariani CPA serves as Chief Financial Officer of the Company. Mr. Mariani has been Axogen’s Chief Financial Officer since March 2016. Prior to joining Axogen, he served as Chief Financial Officer of Lensar, Inc, a privately held laser refractive cataract surgery company, from July 2014 through January 2016, which was sold in December 2015. From June 2011 to June 2014 Mr. Mariani served as Chief Financial Officer of Hansen Medical, a publicly traded medical device company developing robotic solutions for intravascular procedures. From 2007 through 2010 Mr. Mariani served as Chief Financial Officer for two privately held companies: Harlan Laboratories (2007 – 2009); and BMW Constructors (2009 – 2010). From 1994 through 2006 Mr. Mariani served in various senior financial roles with Guidant Corporation, a publicly traded leader in the development and sale of medical devices for the treatment of cardiovascular disease. Mr. Mariani began his career with Guidant Corporation as Director of Corporate Financial Reporting where he supported the initial public offering of Guidant Corporation and ultimately served as Vice President, Controller and Chief Accounting Officer. Mr. Mariani’s experience at Guidant Corporation included two years as Director of Financial Reporting, Guidant Vascular Intervention in Santa Clara, California, and four years in Tokyo, Japan, mostly as Vice President Finance and Administration where he helped to facilitate the conversion and scale of the Japan business from a distributor network to a direct sales and marketing organization. Following the 2006 sale of Guidant Corporation to Boston Scientific Corporation, Mr. Mariani co-led the initial integration of the two companies. From 1987 to 1994, Mr. Mariani worked with Ernst and Young, LLP, where he served a diverse client base as a Certified Public Accountant. Mr. Mariani received a Bachelor of Science Degree in Accounting from Indiana University.
As the Chief Financial Officer of Axogen, the total compensation of Peter Mariani at Axogen is $548,032. There are 4 executives at Axogen getting paid more, with Eric Sandberg having the highest compensation of $1,113,440.
Peter Mariani is 56, he's been the Chief Financial Officer of Axogen since 2016. There are 9 older and 6 younger executives at Axogen. The oldest executive at Axogen Inc. is Guido Neels, 71, who is the Independent Director.
Peter's mailing address filed with the SEC is 13631 Progress Blvd #400, Alachua, FL 32615, USA.
Over the last 14 years, insiders at Axogen have traded over $73,805,978 worth of Axogen stock and bought 504,297 units worth $3,119,117 . The most active insiders traders include James E Deerfield Mgmt L.P...., Guido J Neels и Karen L. Zaderej. On average, Axogen executives and independent directors trade stock every 21 days with the average trade being worth of $455,132. The most recent stock trade was executed by John Johnson on 1 September 2024, trading 11,904 units of AXGN stock currently worth $158,085.
it's time to rethink nerve repair! axogen (nasdaq: axgn) is a medical products company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. people suffer traumatic injuries or undergo surgeries that impact the function of their peripheral nerves daily. damage may cause loss of function and feeling. axogen is bringing the science of nerve repair to life with its avance® nerve graft which axogen believes is the first and only commercially available allograft for bridging nerve discontinuities, axoguard® nerve connector, a coaptation aid allowing for close approximation of severed nerves, and axoguard® nerve protector that protects nerves during the healing process.
Axogen executives and other stock owners filed with the SEC include: